Clinical Trial Update: FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial comparing FOLFOXIRI plus cetuximab vs FOLFOXIRI plus bevacizumab for conversion therapy in right-sided colon cancer with liver metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Liver Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Fudan University | Conditions: Liver Metastasis Colon Cancer | Phase 2 | Status: UNKNOWN